Page 110 - IMO-1-1

Innovative Medicines & Omics SARS-CoV-2 inhibition by quinolines

Chem. 2023;15(17):1569-1582. doi: 10.3390/ph15010021

doi: 10.4155/fmc-2023-0169 35. Laboratory Biosafety Guidance Related to Coronavirus
Disease (COVID-19): Interim Guidance; 2021. Available
25. Vausselin T, Séron K, Lavie M, et al. Identification of a new from: https://www.who.int/publications/i/item/who-wpe-
benzimidazole derivative as an antiviral against hepatitis C
virus. J Virol. 2016;90(19):8422-8434. gih-2021.1 [Last accessed on 2023 Sep 10].
pro
36. Jin Z, Du X, Xu Y, et al. Structure of M from SARS-CoV-2 and
doi: 10.1128/JVI.00404-16
discovery of its inhibitors. Nature. 2020;582(7811):289-293.
26. Ekins S, Freundlich JS, Clark AM, Anantpadma M, Davey RA,
Madrid P. Machine learning models identify molecules active doi: 10.1038/s41586-020-2223-y
against the Ebola virus in vitro. F1000Res. 2015;4:1091. 37. Goyal B, Goyal D. Targeting the dimerization of the main
protease of coronaviruses: A potential broad-spectrum
doi: 10.12688/f1000research.7217.3
therapeutic strategy. ACS Comb Sci. 2020;22(6):297-305.
27. Hu Q, Xiong Y, Zhu GH, et al. The SARS-CoV-2 main doi: 10.1021/acscombsci.0c00058
protease (Mpro): Structure, function, and emerging
therapies for COVID-19. MedComm (2020). 2022;3(3):e151. 38. Uzunova K, Filipova E, Pavlova V, et al. Insights into
antiviral mechanisms of remdesivir, lopinavir/ritonavir and
doi: 10.1002/mco2.151
chloroquine/hydroxychloroquine affecting the new SARS-
28. Zhang L, Lin D, Sun X, et al. Crystal structure of SARS- CoV-2. Biomed Pharmacother. 2020;131:110668.
CoV-2 main protease provides a basis for design of improved
a-ketoamide inhibitors. Science. 2020;368(6489):409-412. doi: 10.1016/j.biopha.2020.110668
39. Patel TK, Patel PB, Barvaliya M, et al. Efficacy and safety
doi: 10.1126/science.abb3405
of lopinavir-ritonavir in COVID-19: A systematic review
29. Achutha AS, Pushpa VL, Suchitra S. Theoretical insights of randomized controlled trials. J Infect Public Health.
into the anti-SARS-CoV-2 activity of chloroquine and its 2021;14(6):740-748.
analogs and in silico screening of main protease inhibitors. doi: 10.1016/j.jiph.2021.03.015
J Proteome Res. 2020;9(11):4706-4717.
40. Habler K, Brügel M, Teupser D, et al. Simultaneous
doi: 10.1021/acs.jproteome.0c00683
quantification of seven repurposed COVID-19 drugs
30. Carmo AM, Silva FM, Machado PA, et al. Synthesis of remdesivir (plus metabolite GS-441524), chloroquine,
4-aminoquinoline analogues and their platinum(II) hydroxychloroquine, lopinavir, ritonavir, favipiravir and
complexes as new antileishmanial and antitubercular agents. azithromycin by a two-dimensional isotope dilution
Biomed Pharmacother. 2011;65(3):204-209. LC-MS/MS method in human serum. J Pharm Biomed Anal.
2021;196:113935.
doi: 10.1016/j.biopha.2011.01.003
doi: 10.1016/j.jpba.2021.113935
31. Calixto SL, Glanzmann N, Xavier Silveira MM, et al.
Novel organic salts based on quinoline derivatives: The 41. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental
in vitro activity trigger apoptosis inhibiting autophagy in and computational approaches to estimate solubility and
Leishmania spp. Chem Biol Interact. 2018;293:141-151. permeability in drug discovery and development settings.
[The article was originally published in Adv Drug Deliv Rev.
doi: 10.1016/j.cbi.2018.08.003
1997;23:3-25]. Adv Drug Deliv Rev. 2001;46(1-3):3-26.
32. Dludla PV, Jack B, Viraragavan A, et al. A dose-dependent
effect of dimethyl sulfoxide on lipid content, cell viability doi: 10.1016/S0169-409X(00)00129-0
and oxidative stress in 3T3-L1 adipocytes. Toxicol 42. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward
Rep. 2018;5:1014-1020. KW, Kopple KD. Molecular properties that influence
the oral bioavailability of drug candidates. J Med Chem.
doi: 10.1016/j.toxrep.2018.10.002
2002;45(12):2615-2623.
33. Fintelman-Rodrigues N, Sacramento CQ, Ribeiro Lima C,
et al. Atazanavir, alone or in combination with ritonavir, doi: 10.1021/jm020017n
inhibits SARS-CoV-2 replication and proinflammatory 43. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP,
cytokine production. Antimicrob Agents Chemother. Ploemen JP. Polar molecular surface as a dominating
2020;64(10):e00825-20. determinant for oral absorption and brain penetration of
doi: 10.1128/AAC.00825-20 drugs. Pharm Res. 1999;16(10):1514-1519.
doi: 10.1023/A:1015040217741
34. Chaves OA, Sacramento CQ, Ferreira AC, et al. Atazanavir
is a competitive inhibitor of SARS-CoV-2 M , impairing 44. Zhu Y, Chidekel A, Shaffer TH. Cultured human airway
pro
variants replication in vitro and in vivo. Pharmaceuticals epithelial cells (Calu-3): A model of human respiratory
(Basel). 2021;15(1):21. function, structure, and inflammatory responses. Crit Care

Volume 1 Issue 1 (2024) 104 doi: 10.36922/imo.3442